Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Valbenazine tosylate by Neurocrine Biosciences for Trichotillomania: Likelihood of Approval
Valbenazine tosylate is under clinical development by Neurocrine Biosciences and currently in Phase II for Trichotillomania. According to GlobalData, Phase...
NBI-1117568 by Neurocrine Biosciences for Schizophrenia: Likelihood of Approval
NBI-1117568 is under clinical development by Neurocrine Biosciences and currently in Phase II for Schizophrenia. According to GlobalData, Phase II...
NBI-1076986 by Neurocrine Biosciences for Movement Disorders: Likelihood of Approval
NBI-1076986 is under clinical development by Neurocrine Biosciences and currently in Phase I for Movement Disorders. According to GlobalData, Phase...
NBI-1070770 by Neurocrine Biosciences for Major Depressive Disorder: Likelihood of Approval
NBI-1070770 is under clinical development by Neurocrine Biosciences and currently in Phase II for Major Depressive Disorder. According to GlobalData,...
NBI-1065845 by Neurocrine Biosciences for Treatment Resistant Depression: Likelihood of Approval
NBI-1065845 is under clinical development by Neurocrine Biosciences and currently in Phase II for Treatment Resistant Depression. According to GlobalData,...
NBI-1065890 by Neurocrine Biosciences for Psychiatric Disorders: Likelihood of Approval
NBI-1065890 is under clinical development by Neurocrine Biosciences and currently in Phase I for Psychiatric Disorders. According to GlobalData, Phase...
NBI-1065845 by Neurocrine Biosciences for Major Depressive Disorder: Likelihood of Approval
NBI-1065845 is under clinical development by Neurocrine Biosciences and currently in Phase II for Major Depressive Disorder. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences's NBI-1065846?
NBI-1065846 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase II program in Cognitive Impairment Associated With...
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences's NBI-1065845?
NBI-1065845 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase II program in Treatment Resistant Depression. According...
Crinecerfont by Neurocrine Biosciences for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome): Likelihood of Approval
Crinecerfont is under clinical development by Neurocrine Biosciences and currently in Pre-Registration for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome). According to...
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences's NBI-1117568?
NBI-1117568 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase II program in Schizophrenia. According to Globaldata,...
Apinocaltamide by Neurocrine Biosciences for Epileptic Encephalopathy: Likelihood of Approval
Apinocaltamide is under clinical development by Neurocrine Biosciences and currently in Phase II for Epileptic Encephalopathy. According to GlobalData, Phase...